|
Agent
|
Targeting site
|
Phase
|
ClinicalTrial.gov ID
|
|---|
|
Endostar
|
Angiogenesis inhibitor
|
II
|
NCT02520219
|
|
Selinexor
|
Selective inhibitor of nuclear export
|
II
|
NCT02314247
|
|
Tipifarnib
|
Farnesyltransferase inhibitor
|
II
|
NCT02464228
|
|
Darinaparsin
|
Organic arsenic compound
|
I
|
NCT01435863
|
|
NCT01689220
|
|
Ixazomib
|
Proteasome inhibitor
|
II
|
NCT02158975
|
|
Denileukin diftitox
|
Interleukin fusion protein
|
II
|
NCT00050999
|
|
NCT00051012
|
|
Forodesine
|
PNP inhibitor
|
I/II
|
NCT01776411
|
|
Ruxolitinib
|
JAK inhibitor
|
II
|
NCT01431209
|
|
Temsirolimus
|
mTOR inhibitor
|
I
|
NCT01614197
|
|
Carfilzomib
|
Proteasome inhibitor
|
I
|
NCT01336920
|
|
Panobinostat
|
Pan-deacetylase inhibitor
|
II
|
NCT01261247
|
|
Clofarabine
|
DNA synthesis inhibitor
|
I/II
|
NCT00644189
|
|
MK2006
|
AKT inhibitor
|
II
|
NCT01258998
|
|
Sorafenib
|
Multikinase inhibitor
|
II
|
NCT00131937
|
|
Alefacept
|
Immunosuppressive dimeric fusion protein
|
I
|
NCT00438802
|
|
Pembrolizumab
|
PD-1 antibody
|
II
|
NCT02535247
|
-
PNP purine nucleoside phosphorylase, JAK Janus kinases, mTOR mammalian target of rapamycin, PD-1 programmed death-1
